IL1B and heart failure: More importantly, those randomised to canakinumab (a human monoclonal anti-IL-1β antibody) who achieved an on-treatment hsCRP concentration of <2 mg/L reported significantly less heart failure hospitalisations and heart failure-related mortality—an effect which was obvious in both individuals with and without a history of heart failure [88].